Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.

To further clarify the anticancer mechanisms of Liujunzi decoction and provide possible targets for the treatment of advanced-stage nonsmall cell lung cancer (NSCLC) by re-analyzing differential gene expression profile of peripheral blood mononuclear cells (PBMCs) from Liujunzi decoctiontreated NSCLC patients receiving first-line chemotherapy.The PBMC gene expression microarray data set GSE61926 was retrieved from a high throughput gene expression database. Differentially expressed genes (DEGs) were screened by paired sample t-test and the multiple ratio method. Gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses were performed using the DAVID database. The protein-protein interaction (PPI) network was constructed using interaction gene library retrieval tools and Cytoscape software.A total of 162 DEGs were identified, with 67 upregulated genes and 95 downregulated genes. The functional distribution of Gene Oncology (GO) genes showed that DEGs were mostly concentrated in extracellular regions, calcium ion binding, and transcriptase activity. KEGG pathway analysis showed that cytokine-cytokine receptor interactions were significantly enriched. PPI network analysis screened out the top 10 central protein-coding genes with the highest nodal degree: IL2, PIWIL4, DICER1, PIWIL2, SAA1, XCL1, IL22RA1, ARHGAP11A, DCP1A, and GDNF. Among them, the central protein-coding gene with the highest node degree was IL2. In addition, the central protein-coding genes with high node degrees and high molecular complex detection (MCODE) scores were PIWIL4, DICER1, PIWIL2, and DCP1A, all of which are related to tumor development.One signaling pathway and 10 central protein-coding genes related to anticancer mechanisms were screened by re-analysis of GSE61926 data. IL2, PIWIL4, DICER1, PIWIL2, and DCP1A may have important roles in the mechanism of Liujunzi decoction treatment against NSCLC. Our results suggest that the anticancer mechanism of Liujunzi decoction may be related to gene silencing by RNA and the biological processes of piwi-interacting RNA and other small RNAs.

通过重新分析六君子汤治疗的接受一线化疗的非小细胞肺癌（NSCLC）患者外周血单个核细胞（PBMC）的差异基因表达谱，进一步阐明六君子汤的抗癌机制，并为晚期非小细胞肺癌的治疗提供可能的靶点。从高通量基因表达数据库中检索到PBMC基因表达微阵列数据集GSE61926。通过配对样本t检验和倍数比方法筛选差异表达基因（DEGs）。使用DAVID数据库进行基因本体论和京都基因与基因组百科全书（KEGG）通路分析。利用交互基因库检索工具和Cytoscape软件构建蛋白质 - 蛋白质相互作用（PPI）网络。 共鉴定出162个差异表达基因，其中67个基因上调，95个基因下调。基因本体论（GO）基因的功能分布显示，差异表达基因主要集中在细胞外区域、钙离子结合和转录酶活性方面。KEGG通路分析显示细胞因子 - 细胞因子受体相互作用显著富集。PPI网络分析筛选出节点度最高的前10个中心蛋白编码基因：IL2、PIWIL4、DICER1、PIWIL2、SAA1、XCL1、IL22RA1、ARHGAP11A、DCP1A和GDNF。其中，节点度最高的中心蛋白编码基因是IL2。此外，节点度高且分子复合物检测（MCODE）得分高的中心蛋白编码基因是PIWIL4、DICER1、PIWIL2和DCP1A，它们都与肿瘤发展有关。 通过对GSE61926数据的重新分析，筛选出一个信号通路和10个与抗癌机制相关的中心蛋白编码基因。IL2、PIWIL4、DICER1、PIWIL2和DCP1A可能在六君子汤治疗非小细胞肺癌的机制中具有重要作用。我们的结果表明，六君子汤的抗癌机制可能与RNA介导的基因沉默以及piwi相互作用RNA和其他小RNA的生物学过程有关。